Profound Medical Corp. (PROF) closed at $6.57 on October 30, 2026, up 12.1% from the previous close, on volume of 469,349 shares (30-day average 262,328).
Data as of October 30, 2026.
30-Oct-2026
Profound Medical Taps Cook iMRI Partnership to Expand TULSA-PRO Reach in U.S.
TipRanks (Fri, 30-Oct 11:39 AM ET)
Globe Newswire (Fri, 30-Oct 8:00 AM ET)
Emmy-Award Winning Television Host Montel Williams to Join Next 'Let's Huddle' Webinar
Globe Newswire (Thu, 22-Oct 4:15 PM ET)
Globe Newswire (Wed, 14-Oct 7:30 AM ET)
Globe Newswire (Fri, 9-Oct 7:45 AM ET)
PROF jumps as preliminary Q3 revenue is pegged 45%–47% above Bloomberg consensus
Market Chameleon (Thu, 8-Oct 6:58 AM ET)
Profound Medical flags record Q3 revenue range that sits roughly 45%–47% above Bloomberg consensus
Market Chameleon (Thu, 8-Oct 3:05 AM ET)
Profound Medical Reports Strong Preliminary Third Quarter 2026 Revenue
Globe Newswire (Wed, 7-Oct 4:15 PM ET)
Profound Medical to Participate in Lake Street's 10th Annual Best Ideas Growth Conference
Globe Newswire (Thu, 3-Sep 8:15 AM ET)
Globe Newswire (Tue, 1-Sep 8:00 AM ET)
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Profound Medical Corp. trades on the NASDAQ stock market under the symbol PROF.
As of October 30, 2026, PROF stock price climbed to $6.57 with 469,349 million shares trading.
PROF has a beta of 1.63, meaning it tends to be more sensitive to market movements. PROF has a correlation of 0.09 to the broad based SPY ETF.
PROF has a market cap of $240.02 million. This is considered a Small Cap stock.
Last quarter Profound Medical Corp. reported $2 million in Revenue and -$.26 earnings per share. This fell short of revenue expectation by $-4 million and missed earnings estimates by -$.02.
In the last 3 years, PROF traded as high as $11.69 and as low as $3.76.
The top ETF exchange traded funds that PROF belongs to (by Net Assets): QQQS, DFIC.
PROF has underperformed the market in the last year with a return of +7.4%, while the SPY ETF gained +12.3%. In the last 3 month period, PROF fell short of the market, returning -9.4%, while SPY returned +2.1%. However, in the most recent 2 weeks PROF has outperformed the stock market by returning +9.3%, while SPY returned -1.0%.
PROF support price is $5.59 and resistance is $6.13 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PROF shares will trade within this expected range on the day.
